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The isolation from brain tumors of tumor mesenchymal stem-like cells (tMSLCs) suggests that these cells play a role in creating a
microenvironment for tumor initiation and progression.The clinical characteristics of patients with primary glioblastoma (pGBM)
positive for tMSLCs have not been determined.This study analyzed samples from82patientswith pGBMwhohadundergone tumor
removal, pathological diagnosis, and isolation of tMSLC from April 2009 to October 2014. Survival, extent of resection, molecular
markers, and tMSLC culture results were statistically evaluated. Median overall survival was 18.6 months, 15.0 months in tMSLC-
positive patients and 29.5 months in tMSLC-negative patients (𝑃 = 0.014). Multivariate cox regression model showed isolation of
tMSLC (OR = 2.5, 95% CI = 1.1∼5.6, 𝑃 = 0.021) showed poor outcome while larger extent of resection (OR = 0.5, 95% CI = 0.2∼0.8,
𝑃 = 0.011) has association with better outcome. The presence of tMSLCs isolated from the specimen of pGBM is associated with
the survival of patient.
1. Introduction
Glioblastomas (GBMs) are generated by interactions between
cancer stem cells (CSCs) and stroma [1–3].The accumulation
of molecular errors in CSCs initiates tumorigenesis, and
these CSCs aggregate with stromal cells, which synergistically
aggravate the disease [4, 5]. Mesenchymal stem-like cells
(MSLCs) have been isolated from normal brain [6, 7] and
Lang et al. [8] presented the isolation of mesenchymal stem
cells (MSCs) fromglioma for the first time. In addition, tumor
MSLCs (tMSLCs) have been isolated from several human
brain tumors [2, 9–11], suggesting that these cells play a role
in creating a microenvironment conducive to brain tumor
initiation and progression [2, 12–14].
GBMs can be grouped into several subtypes, based on
molecular markers, gene expression profiles [15–19], and
chromosomal aberration [20, 21]. Based on their genetic
characteristics, GBMs can be divided into four types, with the
mesenchymal type having the poorest prognosis [17, 18, 22].
Several molecular markers have been shown to be related
to survival benefits in patients with GBM, including O-6-
methylguanine-DNA methyltransferase (MGMT) methyla-
tion and the isocitrate dehydrogenase (IDH) 1/2 mutation
[23–25]. The prognostic value of heterozygosity (LOH) at
chromosomes 1p and 19q, however, is unclear [26, 27]. Iso-
lation of CSCs from primary GBM (pGBM) samples can also
predict the natural course of pGBM [28]. Although tumor
stromal cells were found to have a significant impact on
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patient survival [29, 30], the clinical significance of isolation
of tMSLCs, a type of stromal cells, from pGBM stroma has
not been determined.
We hypothesized that the presence of tMSLCs may
aggravate the natural course of pGBM. This study therefore
assessed whether the presence of tMSLCs in pGBM patients
has an effect on patient survival and prognosis.
2. Materials and Methods
2.1. Patient Information. A total of 82 patients with pGBM
who received standard therapy [31] at two institutions (Sev-
erance Hospital, Yonsei University College of Medicine, and
Seoul St. Mary’s Hospital, the Catholic University of Korea
College of Medicine) from April 2009 to October 2014 were
included in this study (Table 1). We followed up the cohort
from previous report [11] and added new additional patients
that were not included in that report [11]. Approval for harvest
and investigation was obtained from the institutional review
boards of the two institutions, and all patients provided
written informed consent, as specified in the Declaration of
Helsinki. Specimens for isolation of tMSLCswere collected in
the operating theater from patients undergoing surgery. All
surgical specimens were evaluated by two neuropathologists,
who diagnosed each patient according toWorldHealthOrga-
nization (WHO) classifications [32]. Survival, extent of resec-
tion,molecularmarkers, and tMSLC culture results were ana-
lyzed statistically. Inclusion criteria were as follows: the first
pathologic diagnosis of primary glioblastoma patients with
the standard Stupp protocol; radiation dose of 60Gy fraction-
ated by 30 times; and Stupp protocol within 2 weeks after the
pathological diagnosis. Excluded patients met following cri-
teria: recurring glioblastoma after previous surgery; gliosar-
coma; nonstandard dose for temozolomide administration;
hypofractionated radiotherapy; and poor hematologic profile
that delayed normal course of standard treatment.
2.2. Initial Treatment. All patients underwent surgical resec-
tion, aimed at gross total resection of the tumor, followed
by concurrent chemotherapy and radiotherapy and adjuvant
chemotherapy [31]. Gross total tumor resection was defined
as macroscopic removal of 100% or above of the tumor mass
found on magnetic resonance (MR) T1 enhanced and T2
images [33, 34]. Patients not suitable for total resection under-
went subtotal resection, defined as removal of macroscopic
tumor volume ≥90% but <100%, or partial resection, defined
as removal ofmacroscopic tumor volume<90%.The extent of
tumor resectionwas estimated and classified by the neurosur-
geons and rechecked by postoperative review of MR imaging
(MRI) scans. All patients received postoperative adjuvant
radiotherapy with concomitant and adjuvant temozolomide
(TMZ), as described previously [31]. Each patient was offered
standard therapy [31] after pathologic confirmation.The only
factors determining the continuation of standard treatment
were patient tolerance (general condition, laboratory abnor-
malities such as hematologic problems), family agreement for
the treatment, and patient survival. The correlation between
molecular markers (MGMT methylation, p53, 1p LOH, 19q
LOH, Ki67 index, and IDH1 mutation) and survival was
analyzed statistically. MGMT methylation was assessed by
polymerase chain reaction (PCR) and LOH at chromosomes
1p and 19q by fluorescent in situ hybridization (FISH).
2.3. Isolation of tMSLCs. tMSLCs with characteristics similar
to MSCs have been isolated from brain tumor specimens [9–
11]. Specimens from patients with GBM were obtained from
the operating room. Briefly, cells were isolated during tumor
removal using a mechanical dissociation method within 1 h.
Surgical specimens were minced and dissociated with a
scalpel in minimal essential medium-𝛼 (MEM𝛼; Mediatech,
Herndon, VA, USA) and passed through a series of cell
strainers with a 100𝜇m nylon mesh. Cell suspensions were
washed twice in MEM𝛼 and then cultured in complete MSC
medium consisting of MEM𝛼, 10% fetal bovine serum (FBS;
Gibco, Invitrogen), 2mM L-glutamine (Mediatech), and 1x
antibiotic-antimycotic solution (Invitrogen, Carlsbad, CA,
USA). After 24 h, nonadherent cells were removed by wash-
ing twice with phosphate-buffered saline (PBS; Mediatech),
and the adherent cells were cultured until they reached con-
fluence. The cells were then trypsinized (0.25% trypsin with
0.1% EDTA) and subcultured at a density of 5 × 103 cells/cm2.
Isolated cells were evaluated for several mesenchymal fea-
tures, including plastic adhesion, trilineage differentiation,
the presence of typical MSC surface markers (positive for CD
105, CD 90, and CD 72 and negative for CD 45, CD 31, and
NG2), and nontumorigenic behavior [11, 13, 35].
2.4. Statistical Analysis. The primary outcome measure was
median overall survival (OS), defined as the interval from
date of surgery confirming the diagnosis of pGBM to the date
of last follow-up visit or death [36]. Immunohistochemical
analysis of p53 expression was defined as immunopositivity
when the areas with staining of ≥50% of cancer cells were
found. Ki 67 index was defined as immunopositive when
the stained area exceeded 10% or more. Among clinically
deemed primary glioblastomas, 5 patients (6%) hadmutation
on IDH1.They were not excluded from our study for compre-
hensive evaluation. Because of small number of patients with
IDH1 mutation and previous reports about different clinical
characteristics [37], they were not eligible for survival anal-
ysis and excluded from multivariate cox regression model.
Survival was analyzed by the Kaplan-Meier method and
compared by the log-rank test. Demographic characteristics
were compared using Fisher’s exact test or 𝑡-test. All statistical
analyses were performed using SPSS 22 (IBM Korea, Seoul,
Korea), with 𝑃 values less than 0.05 regarded as statistically
significant.
3. Results
3.1. Patient Characteristics. Of the 82 patients with pGBM,
48 (59%) were positive and 34 (41%) negative for tMSLCs
(Table 1), with no group differences in the extent of resection
(𝑃 = 0.471), age (𝑃 = 0.683), and expression of specific
molecular markers (IDH1, 𝑃 = 0.642; MGMT promoter,
𝑃 = 0.653; p53, 𝑃 = 0.522 for positivity 𝑃 = 0.492 for the
percentage of immunohistochemistry; EGFR, 𝑃 = 0.161; Ki
67, 𝑃 = 0.739 for the number of each of the immunostaining
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Table 1: Demographic and clinical characteristics of patients with pGBM.




Age, no. (%) 0.899
<50 years, no. (%) 9 (19) 6 (18)
≥50 years, no. (%) 39 (81) 28 (82)
Gender 0.110
Male, no. (%) 33 (69) 17 (50)
Female, no. (%) 15 (31) 17 (50)
Median survival (months) 15.0 29.5 0.014
95% CI 9.6∼20.4 11.9∼47.1
Pathological diagnosis pGBM pGBM
Treatment OP/Stupp OP/Stupp
Extent of operation (patients) 0.471
Gross total resection (≥100%) 29 (60) 19 (56)
Subtotal resection (90% ≤, <100%) 18 (38) 12 (35)
Partial resection (<90%) 1 (2) 3 (9)
Molecular markers
IDH1 0.642
Wild type, no. (%) 39 (91) 26 (96)
Mutation, no. (%) 4 (9) 1 (4)
Missing data, no. (%) 5 (10) 7 (21)
1p19q 0.341
No codeletion, no. (%) 37 (80) 30 (91)
Median survival (months) 15.0 29.5 0.011
95% CI 8.9∼21.1 9.1∼50.0
Codeletion, no. (%) 9 (20) 3 (9)
Median survival (months) 12.9 9.3 0.886
95% CI 0.8∼25.0 1.6∼17.0
Missing data, no. (%) 2 (4) 1 (3)
MGMT promoter 0.653
Wild type, no. (%) 27 (59) 18 (53)
Median survival (months) 15.0 NA 0.122
95% CI 8.8∼21.2 NA
Methylated, no. (%) 19 (41) 16 (47)
Median survival (months) 18.6 34.1 0.164
95% CI 6.2∼31.0 13.6∼54.6
Missing data, no. (%) 2 (4) 0 (0)
p53 0.522
IHC negative (<50%), no. (%) 23 (77) 13 (65)
Median survival (months) 13.7 NA 0.324
95% CI 9.8∼17.6 NA
IHC positive (≥50%), no. (%) 7 (23) 7 (35)
Median survival (months) 18.6 NA 0.704
95% CI 9.9∼27.3 NA
IHC mean ± S.D. 28.4 ± 27.0 33.9 ± 28.8 0.492
Range (%) 1.5∼85 2.5∼90
Missing data, no. (%) 18 (38) 14 (41)
EGFR
IHC mean ± S.D. 1.9 ± 1.1 2.3 ± 0.9 0.161
Range 0∼3 0∼3
Missing data, no. (%) 6 (13) 7 (21)
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Table 1: Continued.
Characteristics tMSLCs (+) (𝑁 = 48) tMSLCs (−) (𝑁 = 34) 𝑃 value
Ki 67 0.739
IHC negative (<10%), no. (%) 5 (11) 3 (9)
IHC positive (≥10%), no. (%) 40 (89) 31 (91)
IHC % mean ± S.D. 22.6 ± 14.1 30.1 ± 20.2 0.057
Range (%) 2∼60 3∼80
Missing data, no. (%) 3 (6) 0 (0)
S.D.: standard deviation; IDH: isocitrate dehydrogenase; LOH: loss of heterozygosity; OP/Stupp: operation followed by Stupp’s regimen; MGMT: O-6-
methylguanine-DNA methyltransferase; EGFR: epidermal growth factor receptor; NA: not available.
Table 2: Cox proportional hazard regression model of factors prognostic of overall survival in patients with pGBM.
Characteristics Univariate Multivariate
OR 95% CI 𝑃 value OR 95% CI 𝑃 value
Isolation of tMSLCs 2.4 1.2∼5.1 0.017 2.5 1.1∼5.6 0.021
Age ≥ 50 years 1.3 0.5∼3.1 0.587
Extent of resection 0.7 0.4∼1.1 0.151 0.5 0.2∼0.8 0.011
IDH1 mutation 1.6 0.4∼6.7 0.551
LOH 1p19q 1.3 0.6∼3.0 0.532 1.1 0.4∼2.6 0.869
MGMTmethylation 0.8 0.4∼1.6 0.522 0.9 0.4∼1.9 0.792
p53 ≥ 50% 0.7 0.2∼1.8 0.418
EGFR 1.1 0.7∼1.5 0.782
Ki 67 index ≥ 10% 3.3 0.5∼24.7 0.235 5.4 0.7∼42.0 0.107
tMSLCs: tumor mesenchymal stem-like cells; IDH: isocitrate dehydrogenase; LOH: loss of heterozygosity; MGMT: O-6-methylguanine-DNA methyltrans-
ferase; EGFR: epidermal growth factor receptor; OR: odds ratio; CI: confidence interval.
statuses𝑃 = 0.057 for the percentage of immunohistochem-
istry). All of 48 tMSLCs isolated from specimens showed
trilineage differentiation, expression ofMSC surfacemarkers,
and adherence to a plastic plate without gliomagenesis.
3.2. Patient Survival. At a medium follow-up of 11.1 months,
38 patients died. The median survival duration of all pGBM
patients was 18.6 months, 15.0 months in patients positive
for tMSLCs and 29.5 months in patients negative for tMSLCs
(𝑃 = 0.014; Figure 1). The 6-, 12-, and 24-month actuarial
rates were 86%, 60%, and 21%, respectively, in patients
positive for tMSLCs and 93%, 79%, and 61%, respectively, in
patients negative for tMSLCs. From univariate cox propor-
tional regression, the only factor associated with poor sur-
vival was isolation of tMSLCs from the specimen (OR = 2.4,
95% CI = 1.2∼5.1, 𝑃 = 0.017; Table 2). We included extent of
resection, codeletion of 1p19q,MGMTmethylation, andKi 67
index to a multivariate cox model with a result that isolation
of tMSLCs (OR = 2.5, 95% CI = 1.1∼5.6, 𝑃 = 0.021) was
associatedwith poorer outcome and larger extent of resection
had association with better prognosis (OR = 0.5, 95% CI =
0.2∼0.8, 𝑃 = 0.011) while codeletion of 1p19q, MGMT
methylation, and Ki 67 index does not differentiate survival
of patients.
4. Discussion
MSLCs are cells with MSC-like properties that have been
isolated from brain [6, 7], especially from brain tumors
(tMSLCs) [2, 9–11, 13, 38]. These cells possess MSC surface
antigens, show trilineage differentiation, adhere to plastic
plates, and are nontumorigenic [11, 13, 35].
This study found that OS differed significantly between
pGBM patients positive and negative for tMSLCs, suggesting
that tMSLCs may play a role in the progression of pGBM.
Although the “seed and soil” concept of cancer biology was
proposed more than 125 years ago [39–41], GBM tumor-
spheres (TS) have been demonstrated recently [42, 43], with
tMSLCs being a factor in this concept [9–12]. Although the
exact function of tMSLCs in pGBM is not well understood,
this study showed that tMSLCs were clinically important, in
that they were prognostic of survival.The next step should be
to assess the interactions between the GBM TS and tMSLCs.
Our overall survival (18.6 months) was higher than previ-
ously reported paper [31]. Although we described gross total
resection in this paper, we indeed did supratotal resection,
which made longer overall survival in our patients; however
it was not proved through publication. The small number of
patients (82 cases in total) recruited to this retrospective study
is a limitation to interpret the results of this study. Although
we compiled as many patients as possible, only subgroup
that meets strict inclusion and exclusion criteria has limited
number of patients. As our analysis does not show different
prognosis in overall survival that was determined by MGMT
methylation or LOHof 1p19qwhichwas shown inmore inclu-
sive larger patient set, cautious interpretation of our result
is required. In addition, our study included IDH1 mutant
patients and unknown patients, although we described
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Figure 1: Kaplan-Meier estimates of overall survival according to
tMSLCs isolation (𝑃 = 0.014 as calculated by the log-rank test).
pGBM. IDH1 mutant patients should be secondary GBM
but these patients were allocated to both groups without
statistical significance, so we included all IDH1 mutants
patients and unknown patients in this study.
From original group of 82 patients, only five of 70 patients
tested (7.1%) had IDH1 mutations, including one from 27
tMSLC-negative (3.7%) patients and four from 43 tMSLC-
positive (9.3%) patients. While these 5 tumors were not
clinically suspected as secondary glioblastomas, they were
excluded from multivariate cox regression model as the
entity was shown to have different prognosis [37]. Patients
with mutated IDH1 were younger than those with wild type
IDH1 (45.3 versus 60.7 years) [37]. Although LOH at 1p
or 19q was found to correlate with longer OS in patients
with oligodendroglioma [44], the association in patients with
pGBM remains unclear. In our result, codeletion of 1p19q
was not associated with prognosis (univariate: OR = 1.3, 95%
CI = 0.6∼3.0, 𝑃 = 0.532; multivariate: OR = 1.1, 95% CI =
0.4∼2.6, 𝑃 = 0.869). Analysis of MGMT promotor showed
that 42% of specimens were methylated (41% in tMSLCs (+),
47% in tMSLCs (−)) and that median OS tended to be longer
in patients with methylation while lacking statistical signifi-
cance (18.6 versus 15.0 months, 𝑃 = 0.650). IHC analysis of
p53 found that 28%of specimenswere stained for thismarker.
However, median OS was similar in p53 positive and negative
patients (18.6 versus 13.7 months, 𝑃 = 0.415).
In this study, tMSLCswere isolated from58.5%of patients
with pGBM, compared with 46.2% in a previous study
[11]. This increase, despite using the same isolation method,
reemphasizes that isolation of a specific cell type froma tumor
specimen requires a standardized method or may reflect a
learning curve among laboratory staffs. Further researchmay
identify specific cell markers prognostic of OS. We present
novel findings of tMSLCs as a prognostic marker. Several
noteworthy publications have discussed potential roles for
MSLCs in glioma natural history, such as increase in angio-
genesis [12] or increased proliferation and self-renewal of
glioma stem cells [13]. Although we could introduce possible
mechanisms based on published articles [12, 13], this study
could not showanydirect biologicalmechanismof tMSLCs as
prognostic markers, which we believe one of the limitations
of current study.
Mesenchymal features may contribute to poor survival
in patients with brain tumors. Higher grade gliomas [11]
and meningiomas [10] are more likely to be identified to
have tMSLCs. Indeed, tMSLCs could not be isolated from
WHO grade 1 gliomas and meningiomas, whereas 20%, 33%,
and 32% (or 46.2% without secondary GBM and recurrent
GBM) of WHO grade 2, 3, and 4 gliomas, respectively, were
positive for tMSLCs [11]. It remains unclear, however, how the
presence of tMSLCs aggravates the natural history of a brain
tumor or contributes to tumor progression.
5. Conclusion
Isolation of tMSLCs is associated with the survival of pGBM
patients. tMSLCs may have a critical role in the survival of
patients with pGBM. Other cell types may predict the clinical
course of patients with pGBM. In addition, cell surfacemark-
ers and molecular markers of pGBM may have prognostic
value, and the interactions of tMSLCs with gCSCs may better
reveal the role of these cell types in pGBM patients.
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